Try our Advanced Search for more refined results
Life Sciences - June, 2013
294 articles
- 11th Circ. Remands $10M Orders Over Medicare Scheme
- Foley Picks Up Patent Pro From Knobbe Martens
- Teva Sues Reckitt Over UK Generic-Drug Delay Tactics
- Merck, BMS Target Cipla USA Over Generic HIV Drug Sustiva
- Medtronic Hit With Shareholder Suit Over Infuse Studies
- Defending Design Defect Claims? High Court Has Your Back
- Obama's Picks For GSA, NRC Win Senate Approval
- Miss. Can't Bounce Plavix Suit To State Court, Judge Says
- Biosimilars Mark Milestone In Europe With Regulators' Nod
- Pfizer Unit, EPA Reach $2.2M Deal Over CAA Violations
- Painkiller Maker Settles With FDA Over Moldy Meds
- Woman Defends $28M Verdict In Knee Injury Row Rehearing
- Boston Scientific Puts Up $275M For Bard Cardiac Unit
- Merck Off The Hook In Fosamax Fracture Suit, Judge Rules
- Judge Won't Postpone Medicare Competitive Bid Expansion
- Bartlett's Benefits Will Extend Beyond Generic-Drug Makers
- Senate Bill Aims To Reduce Antibiotic Use In Livestock
- EU, US May Get Same Results In Pay-For-Delay Enforcement
- Smith & Nephew Patent Award Too Ambiguous, Judge Rules
- Stryker Can't Force Coverage Of $8M Knee Claims For Now
- FDA, Interpol Seize $41M In Illegal Drugs From Websites
- Ex-'Girls Next Door' Star Sued Over Weight Loss Product
- Texas Court Blocks Challenge To Medicaid Drug Pay Rules
- Ex-J&J Human Resources VP Claims Culture Of Racial Bias
- J&J Units Lodge IP Suit Over Generic Concerta
- High Court To Review Okla. Limits On Abortion Pill Use
- Deals Rumor Mill: ING, KKR, Amgen
- Aspen Makes Another $1B Growth Play With New Merck Deal
- Novartis Beats Failure-To-Warn Suit Over Zometa, Jury Rules
- Imaging3 CEO Misled Investors About 3-D Device, SEC Says
- Scientific Findings Can't Yield False Ad Claims, 2nd Circ. Says
- AbbVie Gets Humira Patent Invalidated As Obvious
- J&J Met $5M CAFA Bar In Aspirin Suits, 8th Circ. Rules
- Pfizer Can't Halt Pay-For-Delay Suit Pending Appeal
- Sandoz Fights Amgen Enbrel Patent
- Pfizer To Pay $964M In Quigley's Approved Ch. 11 Plan
- Wyeth, Cordis Stent Patents Are Invalid, Fed. Circ. Rules
- Daiichi Sankyo Loses Bid To Ship Sex Bias Suit To NJ
- Why Startups Should Focus On Patents Early On
- Medtronic Probed Over Trade Agreements Act Compliance
- Forum Clause Sank Brown Rudnick Suit Only In NJ: Judge
- FDA Sues NJ Compounder Over Mold-Contaminated Products
- FDA Details Pathways For Speedier Drug Approvals
- 11th Circ. Affirms Teva's Win In Suit Over Generic Reglan
- UK Judge Rules J&J Alzheimer Patent Invalid
- GSA, OIRA Nominees Headed For Full Senate Vote
- J&J Unit Asks 3rd Circ. To Nix Cert. In Blood Test Antitrust Row
- FDA Bars Medtronic Catheter Imports Amid 'Serious' Miscues
- Roche Settles Patent Row With Intas Over Cancer Drug Xeloda
- Hikma Sues Eagle Over $3.5M Generic-Drug Rights Deal
- BioVeris Sues Spinoffs Over $4.4M Contract Spat
- Here Comes The Sunshine Act — This Time, In Europe
- What To Know About The Common Interest Privilege
- Goodwin Procter Lands Prosecutor For Securities Team
- More BigLaw Layoffs Expected After Massive Weil Cuts
- High Court's Pass Gives Drug-Patent Safe Harbor Wide Reach
- Door Closes, Window Opens For Generic-Drug Injury Claims
- Lawyers React To High Court's Generic-Drug Liability Ruling
- FDA May Step In After High Court Shields Generic-Drug Cos.
- Deals Rumor Mill: Carrefour, Pharmstandard, Lloyds
- Possible Drug Suit Witness Can See Records Held By MLB
- High Court Vacates 2 Pay-For-Delay Rulings Post-Actavis
- FDA Restricts Cell Therapeutics Drug Trial Following Death
- EU Outlines New Rules On Releasing Drug Trial Data
- Pfizer Hits Alkem, Sandoz With Suits Over Generic Toviaz
- Judge Crushes Medtronic Bone Mill Antitrust Case
- KKR Puts Up $1.3B For Clinical Trial Provider PRA
- High Court Declines To Weigh Reach Of FCA Changes
- Supreme Court Spurns Pfizer Asbestos Liability Fight
- High Court Overturns Landmark Generic-Drug Liability Ruling
- Stiefel Labs Beats Former Exec Suit Claiming $40M Con
- High Court Isn't Keen On Class Actions, Latest Term Shows
- Brown Rudnick Sinks Malpractice Suit Over Medical Sales Row
- Judge Frowns At Insurer's Bid To Dodge Wrinkle Gel Coverage
- Plaintiffs Lawyers Still Hopeful After AmEx Ruling
- Pfizer Wins NJ Choice Of Law Ruling In HRT Mass Tort
- Myriad Ruling Vs. Biotech Patent Eligibility In Europe
- Concerns Over Drug Compounding Bills On Capitol Hill
- Vital Can't Shed Redline Energy Drink Class Action
- Lawmakers Call For Probe Of Medicare Bidding Program
- 'Black Box Warning' Counters Levaquin Claims, Judge Says
- FDA Floats Rule Tweaking Standards For Laser Products
- 'Free And Clear' Means Free And Clear
- EU Greenlights Deal For Faster US Drug Imports
- Endo To Pay $54M In Vaginal Mesh Settlement
- FDA Approves Plan B One-Step For Women Of All Ages
- Justices' AmEx Ruling Greenlights Class Action Waivers
- Surgical Centers File $15M Lawsuit Against Lap-Band Maker
- Attorneys React To High Court's Arbitration Ruling
- DOJ Sues Drugmaker Over Unapproved Misbranded Drugs
- What The High Court's AmEx Ruling Means For Corporations
- Stem Cell Co. Hits Ex-CEO With Trade Secrets Suit
- FDA Hits Drug Repackager With Mislabeling Suit
- Senate Dems Escalate Budget Battle With $1T Spending Plan
- Stryker Awarded $4.6M For Artificial Knee Litigation Coverage
- Examining The Scope Of FDA's 510(k) Recission Authority
- High-Tech Treatments Threaten Medicare Budget, Trustee Says
- Lawmakers Call For Stem Cell Research Backing At NIH
- Supreme Court Says Concepcion Covers Antitrust Cases
- Judge Boosts Royalty Rate For Syntrix's Win in Patent Row
- Sens. Say Pay-For-Delay Legislation Still Needed
- Medical Supplier Group Sues HHS To Delay Competitive Bids
- Plan B Saga Exposes FDA To Drug-Approval Suits
- Shareholder's Securities Suit Against Nautilus Tossed
- Teva Ends Class Suit With $1.3M Deal To Publicize Execs' Pay
- Judge Gives Final OK To $35M GSK Flonase Settlement
- Dynavax Accused Of Duping Investors About Hepatitis Vaccine
- Investor Sues To Block Suspected Icahn Herbalife Deal
- Justices At Odds With 3rd Circ. On Pay-For-Delay, Merck Says
- Covington Fights Doc Request In Prograf Antitrust Row
- Actavis Sues Sandoz, Hetero Over Generic Prostate Drug
- EU Fines Lundbeck $125.6M In Pay-For-Delay Probe
- Evaluating Reverse Payment Settlements After Actavis
- 5 Arguments To Look For In Pay-For-Delay Cases
- Takeda Notches Trial Win In Prevacid Patent Battle
- Reps. Label CMS Evasive, Push Bill To Delay Competitive Bids
- Novo Diabetes Drug Patent Is Obvious, Fed. Circ. Rules
- Rotech Equity Holders Lose Bid To Hire Moelis As Adviser
- Merck, Bristol-Myers Sued Over Diabetes Drugs' Cancer Risks
- Merck Investors Cut Claims In Securities Fraud MDL
- House Lawmakers Blast FDA For $1B User Fee Surplus
- Scott & Scott To Lead SAC Insider Trading Class Action
- Supplement Co. CEO Convicted Again After 9th Circ. Reversal
- Aspen Makes Play For GSK Thrombosis Drugs, Facility
- 2 Deaths Prompt FDA Probe Of Eli Lilly's Zyprexa Relprevv
- Keeping Tabs On 'Natural' Beauty And Food
- Deals Rumor Mill: Johnson Controls, Verizon, Apollo
- UK Joint Ventures: Sanctions And Corruption Risks
- Royalty Pharma Drops $8B Hostile Bid For Elan
- Pay-For-Delay Suits Get New Life Following High Court Ruling
- High Court Pay-For-Delay Ruling To Revamp Drug Patent Deals
- FTC Fought Long, Hard Battle Against Pay-For-Delay Deals
- AbbVie Targets Mylan In Latest Effort To Shield Norvir Patents
- Big Pharma's Legal Bill To Take Hit From Pay-For-Delay Ruling
- Lawyers Comment On High Court's Pay-For-Delay Decision
- Merck, Pfizer Sue Mylan Over Generic Eye Drug Application
- High Court Brings Economics Back To Pay-For-Delay Analysis
- Bayer Wants Tolling Order Nixed In $100M Sex Bias Suit
- Deals Rumor Mill: KKR, AT&T, Fiat
- Fresenius Hit With Dialysis Treatment Class Action
- J&J Inks $1B Deal To Acquire Aragon Pharmaceuticals
- Cinven Strikes $2B Deal For Rockwood's CeramTec
- DePuy Synthes Wins $16M Patent Verdict Against Globus
- Elan Vote Puts Royalty's $8B Hostile Bid In Doubt
- Pay-For-Delay Deals Can Be Illegal, Justices Rule
- NJ Victories For Novartis To Curb Zometa Pile-On Suits
- Generic Drug Labeling Claims Not Preempted By Mensing
- McKesson Dodges Warehouse Worker's Wage-Hour Action
- German Court Sides With Medtronic In Heart Valve Patent Row
- Takeda, Lupin Trim Claims In Prevacid Patent Suit
- Judge Approves $150M Flonase Antitrust Accord
- Ala. High Court To Reconsider Landmark Generic-Drug Ruling
- 8th Circ. Shields Branded Cos. For Generic-Drug Harm
- Shire Settles Intuniv Infringement Case Against Impax
- Novartis Can't Duck Elidel FCA Suit, But Kickback Claims Cut
- Elan Puts Itself Up For Sale To Avert Royalty's $8B Hostile Bid
- Deals Rumor Mill: Vodafone, Siemens, KKR
- FDA Details Clinical Trial Criteria For Combo Drugs
- Nearly All Asbestos Claimants Back New Quigley Ch. 11 Plan
- Takeaways From Largest Drug Safety Settlement
- Promega Gets Patent Claims Invalidated In DNA Analysis Row
- Attorneys React To High Court's Gene Patent Ruling
- High Court's Myriad Ruling Will Spur Novel Patent Claims
- High Court's Myriad Ruling Won't Crush Biotech Industry
- Calif. Case Gives FDA Chance To Tackle 'All-Natural' Labels
- Myriad Ruling: Some Clarity, Some Uncertainty For Biotech
- Scalia Won't Sign Off On DNA Science In Gene Ruling
- Axiom's Trade Secret, Fraud Claims Cut In Trademark Row
- Is TAR Right For Your Discovery Project?
- Suits Over 2 Stryker Hip Implants Combined Into Minn. MDL
- FDA Sued For Questioning Lupus Product's Label
- Stryker Escapes FCA Whistleblower Suit Over Pain Pumps
- FDA Pushes For Increased Medical Device Cybersecurity
- Irish Court Keeps Royalty's Hostile $8B Elan Bid Alive
- Isolated DNA Cannot Be Patented, High Court Rules
- 1st Circ. Won't Revive J&J Whistleblower's Kickback Suit
- DOJ's Compromise On Plan B Access Justified, Judge Says
- Warner Chilcott Can't Duck Consolidated Doryx Antitrust Row
- UK Moves To Regulate E-Cigarettes As Medicine
- Baxter Gets FDA Warning Letter Over Mold, Hair
- Health Clinic Can't Dodge MLB's Drug Suit
- Class Arbitration Is Back In Arbitrators' Hands
- The New Frontier Of Agreements To Negotiate
- Axiom Trademark Beef Gets New Shot In Ex-Employee Row
- Senators Push Shelanski To Curb Oversight Costs And Delays
- We're No Pyramid Scheme, Herbalife Tells Ackman
- E-Discovery Sword May Not Be Sharp Enough
- Pfizer Lands $2.15B Settlement From Teva, Sun Over Protonix
- Judge Ups Royalty Rates In $101M NuVasive Patent Verdict
- Catheter Co. Wants 'Copycat' Boston Scientific Device Banned
- Merck Drops ITC Probe Into Patented Folate Supplements
- 5th Circ. Tells Watson It Can't Review Fentanyl Jurisdiction
- Reps. Call On CMS To Delay Start Of Competitive Bidding
- Genentech Faces Arbitration Over Cancer Drug Licensing
- Royalty Goes On Offense In Ireland Over $8B Elan Bid
- Walgreens To Pay $80M To End Painkiller Sales Probe
- Takeda Diabetes Drug Caused Fatal Bladder Cancer, Suit Says
- Ex-Stiefel Employee Says Co. Bilked Him Of Full Stock Price
- Novartis Sued Over Cancer Drug's Patent Validity
- When A 3rd-Party Use Is A 'Public' Use
- Class Action Attys React To High Court's Arbitration Ruling
- Fed. Circ. Junks Merck's Nasonex Patent Suit Against Apotex
- High Court Ruling Pushes Cos. To Tighten Arbitration Deals
- 5 Tips For An Airtight Approach To ACA Sunshine Rule
- White House Drops Effort To Restrict OTC Morning-After Pills
- Baxter Bosses Sued Over $588M Pump Recall, Plasma Prices
- DOL Tip-Pooling Loss May Spur More Agency Rule Challenges
- Elan Drops Suit After Royalty Opens Up On $8B Hostile Bid
- FDA Balks At Renal Cancer Drug From Aveo, Astellas
- Ex-Bristol-Myers Squibb Exec Admits To Insider Trading
- Shire Says Patent Deals Didn't Block Generic Adderall
- Sens. Want Quick Vote On Drug Compounder Oversight Bill
- High Court Urged To Ban Injunctions On Patent Infringement
- SEC Probing Cardiovascular Systems Over PE Firm's Trading
- Justices Defer To Arbitrator On Oxford Class Arbitration
- GSK Thalidomide Suit To Stay In Fed. Court: 3rd Circ.
- Flector FCA Suit Short On Evidence, Pfizer Unit Says
- AstraZeneca Inks Back-Loaded $1.15B Deal For US Drugmaker
- FCPA Powerhouse: WilmerHale
- Dear Mobile Medical App Developers ...
- Do-Or-Die For Four M&A Deals This Week
- Eisai Destroyed Evidence In Antitrust Case, Sanofi Says
- K-V Judge Signs Off On Investors' $275M Plan
- No Proof Patterson Atty Shared Trade Secrets, J&J Says
- Everett Hits Rival Acella With 2 Prenatal Patent Suits
- Stiefel Crying Wolf Over Worker's $2M Win, 11th Circ. Told
- Ex-InterMune Official Settles SEC Insider Trading Suit
- Claims Trimmed In Abbott Baby Formula Contamination Suit
- Google Threatened With Subpoena Over Painkiller Searches
- MDL Panel Combines Suboxone Antitrust Cases In Pa.
- Deals Rumor Mill: Fiat, Icahn, HSBC
- Royalty Pharma Makes Sweetened $8B Bid For Elan
- Fresenius Targets Actavis With IP Suit Over Diprivan
- FCPA Powerhouse: Willkie Farr
- When In Doubt, Write Your Doctor A Letter
- AbbVie Hits Dr. Reddy's With IP Suit Over Generic Zemplar
- Chemistry Journal Defamed Cardiac Testing Co., Suit Says
- TCPA Junk Fax Suit Against J&J Unit Wins 2nd Chance
- Bard Limits Plaintiffs' Expert Testimony In Vaginal Mesh MDL
- FCPA Powerhouse: Venable LLP
- FDA Can't Regulate Lab Tests As Devices, Group Says
- FDA Panel Backs Looser Limits On GSK's Avandia
- Teva Settles With BMS, Merck Over HIV Drug Generic Plans
- Royalty In 'Wait-And-See' Mode With $6.3B Elan Tender Offer
- Faegre Baker Daniels To Open New Office In Silicon Valley
- West-Ward Pharma Drops False Ad Suit Against Rivals
- Infringement Liability May Exist For Foreign Manufacturers
- 1st Circ. Ruling Highlights Split On FCA First-To-File Bar
- Fla. Pharmacy Says Walgreens Lifted Its 'Teamcare' Mark
- Mediators, Expand Your Tool Kit In Complex Litigation
- Texas Court Urged To Toss $4M Fen-Phen Referral Fee Award
- 9th Circ. Revives ERISA Action Over Amgen Stock Drop
- 2nd Circ. Rejects Delay Of OTC Morning-After Pill
- Biosimilars Dodge State Roadblocks, But Big Hurdles Remain
- Abbott Can't Kick Investor Suit Over Depakote Marketing
- Ex-SAC Manager Gets Date For Insider Trading Trial
- Review Of GSK's Avandia Trial Flawed, FDA Official Says
- Handa's Generic Dexilant Infringes Takeda IP, Judge Hears
- Elan Withdraws Irish Bid To Block Royalty Takeover
- IRS Withholding $125M Owed In Abbott Case, Va. AG Says
- Momenta Urges Justices To Clarify Drug Safe Harbor Rule
- Ex-Becton Engineer Accused Of Lifting Trade Secrets
- Braintree Beats Colon-Cleanser Patent Invalidity Claims
- FCPA Powerhouse: Reed Smith
- Merck Sues Watson Labs To Block Generic Contraceptive
- New Opportunities For VC-Backed Life Sciences Cos.
- Elan Wins Injunctions, But Hostile Bidder Gets ISS Support
- Public Health Workers Urge FDA Action On Antibiotics
- Illumina Trashes Life Tech's Bid To Upset DNA Patent Win
- Merck Presses Fed. Circ. To Reopen Nasonex Battle
- J&J Issues Global Recall Of Cilest Birth Control Pills
- Purchasers Seek Covington Docs In Prograf Antitrust Row
- Rembrandt Asks Fed. Circ. To Revive J&J Contact Lens Row
- Fetal Viability Rule Doesn't Nix Paxil Suit, Pa. Court Told
- Mylan Must Produce Blood Pressure Meds In Apotex IP Row
- Sebelius Likens ACA Fundraising To Previous GOP Efforts
- After FDA Review, GSK Could Earn Reprieve On Avandia
- Not-So-Sunny Requirements Of CMS' Sunshine Act
- Bristol-Myers Copay Subsidies Not Bribes, Judge Finds
- Takeda, Eli Lilly Want Ark. Taxpayer's Actos Suit Nixed
- Vitamin C Co. Pushes To Ax $153M Antitrust Award
- AstraZeneca Unit's Ch. 11 Case Gets The Ax
- Omthera Investor Challenges $443M AstraZeneca Buyout
- Shire Says Patent Settlements Didn't Delay Generic Adderall
- FDA Clarifies Modification Process For Blood Products
- Fed. Circ. Affirms AGA Patent Win In Heart Device IP Row
- Justices Pass On 2nd Circ. Fosamax Jaw-Injury Ruling
- Axiom Wins Infringement Ruling In Device Trademark Row
- Maxygen Says It Will Liquidate, Pay Off Shareholders
- FCPA Powerhouse: Gibson Dunn
- Pfizer, GSK Price-Fixing Suit Won't Get High Court Review
- FCA First-To-File Rule Sinks Kickback Suit, 1st Circ. Says
- IOM Report — Worth Its Salt For Future Health Policy
- Don't Use 'Could You Patent The Sun?' Against Myriad